MedTrace Logo

Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study

NCT02700477 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2016-03-07

No results posted yet for this study

Summary

Trigonella Foenum-Graecum, commonly known as Fenugreek, is a plant that has been extensively used as a source of anti-diabetic compounds Fenugreek is traditionally used in India, especially in the Ayurvedic and Unani systems.

Preliminary animal and human trials suggest possible hypoglycemic and anti-hyper lipidemic properties of Fenugreek seed powder, when taken orally. Fenugreek seeds contain 50% fiber (30% soluble fiber and 20% insoluble fiber) that can slow the rate of post-prandial glucose absorption. This may be a secondary mechanism for the hypoglycemic effect.

Conditions

Interventions

DIETARY_SUPPLEMENT

Fenugreek seeds extract

Fenugreek seed extract 500mg, BD

OTHER

Placebo

Placebo capsule containing Dicalcium Phosphate 500mg, BD

Sponsors & Collaborators

  • Chemical Resources

    lead INDUSTRY

Principal Investigators

  • Dr Narsingh Verma, MD · Dept of Physiology,King George's Medical University, Lucknow, UP, India

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-05-31
Completion
2014-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02700477 on ClinicalTrials.gov